Wandercraft Acquired Robotics Rival Ekso Bionics
The merger aims to scale access to robotic mobility solutions by combining expertise in physical AI and clinical rehabilitation.
Updated on Oct. 9, 2026 in Robotics
Live Poll
Do you believe consolidation of medical robotics companies will lead to better care for patients?
Wandercraft has acquired Ekso Bionics in a move to consolidate expertise in robotic mobility and rehabilitation. The transaction, announced on October 8, 2026, combines Wandercraft's development in physical AI with the established commercial and clinical footprint of Ekso Bionics.
Why it matters
This merger signals a push to bridge the gap between advanced robotics research and widespread clinical application. By unifying these platforms, the combined entity seeks to expand access to assistive mobility devices for rehabilitation professionals and patients alike.
The acquisition merges two distinct platforms: the Atalante X, a self-balancing robotic exoskeleton developed by Wandercraft, and the EksoNR, a medical device for neuro-rehabilitation from Ekso Bionics. Financial details of the deal remain undisclosed.
The players
Wandercraft
A developer of self-balancing robotic exoskeletons and physical AI based in New York and EMEA.
Ekso Bionics
A medical device company recognized for the EksoNR exoskeleton used in physical rehabilitation centers across the United States.
The details
The acquisition integrates Wandercraft's focus on physical AI—software systems that enable robots to navigate and interact with complex physical environments—with the specialized clinical reach of Ekso Bionics. Rehabilitation centers will now gain access to a unified ecosystem of devices, specifically the Atalante X and EksoNR platforms. These systems are designed to assist patients in regaining mobility through powered, gait-assisting exoskeletons that provide tailored support during clinical sessions.
Timeline
October 8, 2026: The acquisition was formally announced.
The Tech Race
This deal consolidates two major players in the competitive field of medical robotics, where devices like the EksoNR have set the standard for clinical gait rehabilitation. The integration positions the combined entity to accelerate the deployment of physical AI across professional rehabilitation networks.
Rehabilitation professionals can expect to consult specialists regarding a unified portfolio of Atalante X and EksoNR systems. Patients will see the impact as these combined technologies become accessible through a single, broader provider network.
The takeaway
The acquisition creates a single point of entry for high-end robotic mobility tools, potentially streamlining device adoption in clinical settings. Readers should watch for future updates regarding the unified product roadmap and potential integration timelines for the Atalante X and EksoNR.
Further reading
For broader trends in medical automation, explore more in Robotics.
Source note: This article includes information reported by MDDI Online.
Live Poll
Do you believe consolidation of medical robotics companies will lead to better care for patients?
